August 10, 2017 / 11:14 AM / 12 days ago

BRIEF-Sierra Oncology reports qtrly loss per share $‍0.20​

Aug 10 (Reuters) - Sierra Oncology Inc

* Sierra Oncology reports second quarter 2017 results

* ‍on track to provide preliminary update from CHK1 inhibitor SRA737 clinical trials in early 2018​

* ‍$116.7 million cash at June 30, 2017 projected to fund current operating plans through approximately mid-2019​

* Qtrly loss per share $‍0.20​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below